TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34677608

Group type: EXPERIMENTAL
Intervention: Metreleptin therapy
Number of subjects: 67

Group type: COMPARATOR
Intervention: RIA leptin assay
Number of subjects: 67

Group type: COMPARATOR
Intervention: MELISA leptin assay
Number of subjects: 67

Group type: COMPARATOR
Intervention: RDELISA leptin assay
Number of subjects: 67
Study: 34678156

Group type: EXPERIMENTAL
Intervention: PSA screening in MSH2 carriers
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: PSA screening in MSH6 carriers
Number of subjects: 828

Group type: COMPARATOR
Intervention: PSA screening in MSH2 non-carrier controls
Number of subjects: 828

Group type: COMPARATOR
Intervention: PSA screening in MSH6 non-carrier controls
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Overall positive predictive value of biopsy using PSA threshold of 3.0 ng/mL
Number of subjects: 828

Group type: EXPERIMENTAL
Intervention: Overall positive predictive value of PSA threshold of 3.0 ng/mL
Number of subjects: 828
Study: 34678329

Group type: EXPERIMENTAL
Intervention: Expect With Me (EWM) group prenatal care
Number of subjects: 2402

Group type: EXPERIMENTAL
Intervention: Expect With Me (EWM) group prenatal care (using integrated information technology platform)
Number of subjects: 2402

Group type: COMPARATOR
Intervention: Individual care only
Number of subjects: 2402
Study: 34678678

Group type: COMPARATOR
Intervention: Trastuzumab alone (4 mg/kg initial dose then 2 mg/kg weekly for 5 weeks)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Trastuzumab combined with everolimus (10 mg/day for 6 weeks)
Number of subjects: 82
Study: 34678750

Group type: EXPERIMENTAL
Intervention: Newspapers
Number of subjects: 4921

Group type: EXPERIMENTAL
Intervention: Social media
Number of subjects: 4921

Group type: EXPERIMENTAL
Intervention: Online interactive media
Number of subjects: 4921

Group type: EXPERIMENTAL
Intervention: Traditional media
Number of subjects: 4921

Group type: EXPERIMENTAL
Intervention: Avoidance of COVID-19-related information
Number of subjects: 4921
Study: 34678845

Group type: EXPERIMENTAL
Intervention: Doppler-based resistive index
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Semiquantitative evaluation of renal perfusion
Number of subjects: 371

Group type: COMPARATOR
Intervention: Doppler-based measurements by expert operators
Number of subjects: 371

Group type: COMPARATOR
Intervention: Doppler-based measurements by nonexpert operators
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for resistive index
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for semiquantitative evaluation of renal perfusion
Number of subjects: 371
Study: 34678870

Group type: EXPERIMENTAL
Intervention: IC14 (atibuclimab) 2 mg/kg IV followed by 1 mg/kg/d IV × 3 (n=3)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: IC14 (atibuclimab) 4 mg/kg IV followed by 2 mg/kg/d IV × 3 (n=7)
Number of subjects: 10
Study: 34681128

Group type: EXPERIMENTAL
Intervention: Surgical masks
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: FFP3 filtering respirators
Number of subjects: 63
Study: 34682453

Group type: EXPERIMENTAL
Intervention: Global Postural Reeducation (GPR group)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Specific Therapeutic Exercises (STE group)
Number of subjects: 62
Study: 34682794

Group type: EXPERIMENTAL
Intervention: Hospitalization for myocarditis
Number of subjects: 19978

Group type: EXPERIMENTAL
Intervention: Heart failure/cardiomyopathy hospitalization
Number of subjects: 19978

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation hospitalization
Number of subjects: 19978

Group type: EXPERIMENTAL
Intervention: Five-year survival rates
Number of subjects: 19978

Group type: EXPERIMENTAL
Intervention: Incidence trends
Number of subjects: 19978

Group type: EXPERIMENTAL
Intervention: Diagnostic tests performance
Number of subjects: 19978

Group type: EXPERIMENTAL
Intervention: Survival rates comparison
Number of subjects: 19978
Study: 34683180

Group type: EXPERIMENTAL
Intervention: Genetic testing including 50 single nucleotide polymorphisms (SNPs) from 39 genes
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Satisfactory response to BS defined as nadir excess weight loss >50%
Number of subjects: 416
Study: 34684360

Group type: EXPERIMENTAL
Intervention: FIT2 program (smoking cessation therapy with individualized coaching in diet and physical activity strategies for PCWG restriction)
Number of subjects: 590

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 590
Study: 34684372

Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed formula (pHF) containing low lactose and probiotics
Number of subjects: 80
Study: 34684546

Group type: EXPERIMENTAL
Intervention: Food intake intervention (not specified in detail)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical activity evaluation (not specified in detail)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anthropometric measurements (not specified in detail)
Number of subjects: 0
Study: 34685448

Group type: EXPERIMENTAL
Intervention: BNT162b2 mRNA vaccine
Number of subjects: 308
Study: 34685481

Group type: EXPERIMENTAL
Intervention: Psychomotor Vigilance Test (PVT) during total sleep deprivation
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Go/noGo executive inhibition task during total sleep deprivation
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Karolinska Sleepiness Scale (KSS) during total sleep deprivation
Number of subjects: 47
Study: 34686180

Group type: EXPERIMENTAL
Intervention: Multimodal exercise and functional rehabilitation program (1 month duration)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard clinical practice care and normal health education program at discharge
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Multimodal exercise and functional rehabilitation program
Number of subjects: 50
Study: 34686309

Group type: EXPERIMENTAL
Intervention: PEEP 8 cm H2O and tidal volume settings
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: PEEP 10 cm H2O and tidal volume settings
Number of subjects: 43
Study: 34686340

Group type: EXPERIMENTAL
Intervention: Targeting TREM2 on tumor-associated macrophages
Number of subjects: 0
Study: 34686372

Group type: EXPERIMENTAL
Intervention: Maternal serum albumin (MAlb) level <36.1 g/L
Number of subjects: 3065

Group type: EXPERIMENTAL
Intervention: Maternal serum albumin (MAlb) level >36.1 g/L
Number of subjects: 3065

Group type: EXPERIMENTAL
Intervention: Maternal serum albumin (MAlb) levels
Number of subjects: 3065
Study: 34686555

Group type: EXPERIMENTAL
Intervention: Total hip arthroplasty (THA) followed by standard care
Number of subjects: 120

Group type: COMPARATOR
Intervention: 12 weeks of supervised progressive resistance training (PRT) followed by 12 weeks of optional unsupervised PRT
Number of subjects: 120
Study: 34686556

Group type: EXPERIMENTAL
Intervention: Neutrophil phagocytic activity
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Immature granulocyte (IG) count
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Plasma cell-free DNA (cfDNA) levels
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Daily screening for sepsis using the 2007 American Burn Association diagnostic criteria
Number of subjects: 245

Group type: EXPERIMENTAL
Intervention: Daily multiple organ dysfunction syndrome and Sequential Organ Failure Assessment Scores
Number of subjects: 245
Study: 34686642

Group type: EXPERIMENTAL
Intervention: PTSD subjects (n = 107; 22%)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: PTSD comorbidity
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Childhood emotional abuse
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: PTSD comorbidity after 6 weeks of antidepressant use
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Childhood emotional abuse, subthreshold hypomania, DMX
Number of subjects: 482
Study: 34686832

Group type: EXPERIMENTAL
Intervention: ROP stage ≤3 without intervention
Number of subjects: 506

Group type: COMPARATOR
Intervention: Children without ROP
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: ROP with intervention
Number of subjects: 506
Study: 34686934

Group type: EXPERIMENTAL
Intervention: Preoperative MRI
Number of subjects: 19324

Group type: COMPARATOR
Intervention: Control (no preoperative MRI)
Number of subjects: 19324
Study: 34687040

Group type: EXPERIMENTAL
Intervention: Bamlanivimab 700 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bamlanivimab 175-500 mg
Number of subjects: 0
Study: 34687334

Group type: EXPERIMENTAL
Intervention: Lung ultrasonography (LUS) as a first-line imaging technique
Number of subjects: 177

Group type: COMPARATOR
Intervention: Chest X-ray (CXR) as a first-line imaging technique (historical control)
Number of subjects: 177
Study: 34687401

Group type: EXPERIMENTAL
Intervention: Smartphone ownership
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Internet access via smartphone
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Access to unlimited data
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Frequent use of text messaging
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Frequent use of email
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Frequent use of health-oriented applications
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: mHealth interventions effectiveness
Number of subjects: 157
Study: 34687412

Group type: EXPERIMENTAL
Intervention: MRI measures of subcutaneous adipose tissue in women with BCRL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (healthy participants)
Number of subjects: 0
Study: 34687548

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam (50-12.5 mg/kg q8h for those ≥6 months to 18 years old; 40-10 mg/kg q8h for those ≥3 to 6 months old)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam
Number of subjects: 0
Study: 34687691

Group type: EXPERIMENTAL
Intervention: Volumetric capnography measurements
Number of subjects: 143
Study: 34687726

Group type: EXPERIMENTAL
Intervention: Senolytic treatment (specific details on dosage and duration not available)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Senolytic trials (NCT04063124 and NCT04685590)
Number of subjects: 0
Study: 34687939

Group type: EXPERIMENTAL
Intervention: First HSCT
Number of subjects: 46

Group type: COMPARATOR
Intervention: Prior blinatumomab therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Prior inotuzumab therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: ≥5 prior lines of therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: ≥5% blasts (M2/M3 marrow) pre-CAR T cell therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Primary refractory disease
Number of subjects: 46
Study: 34688250

Group type: EXPERIMENTAL
Intervention: Larotinib 350 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Larotinib 250 mg and 300 mg
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Larotinib (all doses)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Larotinib (350 mg)
Number of subjects: 81
Study: 34688256

Group type: EXPERIMENTAL
Intervention: Dynamic Gadoxetate-enhanced (DGE) liver MRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG) liver function test
Number of subjects: 0
Study: 34688272

Group type: EXPERIMENTAL
Intervention: Biopsychosocial model of cancer-related fatigue (CRF)
Number of subjects: 200
Study: 34688291

Group type: EXPERIMENTAL
Intervention: Quit Card Intervention (QCI) - includes a 'Quit Card' worth $300 for nicotine replacement therapy, a self-help booklet, and 6 months of telephone follow-up counseling.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC) - includes a brochure for a local smoking cessation program.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quit Card Intervention (QCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study: 34688290

Group type: EXPERIMENTAL
Intervention: Itch Numeric Rating Scale (NRS)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Skin Pain Numeric Rating Scale (NRS)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Atopic Dermatitis Sleep Scale (ADSS)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Thresholds for interpreting meaningful change
Number of subjects: 3
Study: 34688997

Group type: EXPERIMENTAL
Intervention: Whole-exome sequencing in Cohort 1
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Targeted capture sequencing in Cohort 2
Number of subjects: 5
Study: 34689233

Group type: EXPERIMENTAL
Intervention: ICIs combined with regorafenib
Number of subjects: 84
Study: 34689733

Group type: EXPERIMENTAL
Intervention: Recovery-oriented practice training (one-week training session)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Years of professional experience
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nurses and peer workers' roles
Number of subjects: 66
Study: 34689830

Group type: EXPERIMENTAL
Intervention: Peer-delivered decision coaching intervention
Number of subjects: 20
Study: 34690090

Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine
Number of subjects: 145
Study: 34690269

Group type: EXPERIMENTAL
Intervention: Preoperative central graft thickness (CGT) >130 μm
Number of subjects: 108

Group type: COMPARATOR
Intervention: Preoperative central graft thickness (CGT) ≤130 μm
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Postoperative central graft thickness (CGT) >100 μm
Number of subjects: 108

Group type: COMPARATOR
Intervention: Postoperative central graft thickness (CGT) ≤100 μm
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Thin 6-month postoperative grafts
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 6-month postoperative CGT
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Preoperative CGT
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Postoperative DSAEK-CGT
Number of subjects: 108
Study: 34690671

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 28
Study: 34690736

Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling for 20-50 mins, three times a week for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Low-intensity stretching
Number of subjects: 60
Study: 34690824

Group type: EXPERIMENTAL
Intervention: Comorbid Alcohol Use Disorder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without alcohol use disorder)
Number of subjects: 0
Study: 34690831

Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation (tDCS), details on dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 34690837

Group type: EXPERIMENTAL
Intervention: Program for the Education and Enrichment of Relational Skills for Young Adults (PEERS®-YA-K)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study: 34691079

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) initiation
Number of subjects: 0
Study: 34691243

Group type: EXPERIMENTAL
Intervention: Capecitabine in combination with bendamustine
Number of subjects: 40
Study: 34692392

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 117

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 117
Study: 34692470

Group type: EXPERIMENTAL
Intervention: TTFields/TMZ combination
Number of subjects: 134

Group type: COMPARATOR
Intervention: TMZ monotherapy
Number of subjects: 134
Study: 34692757

Group type: EXPERIMENTAL
Intervention: Perineal nerve block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study: 34692764

Group type: EXPERIMENTAL
Intervention: Freehand Stereotactic Image-Guidance
Number of subjects: 0
Study: 34692846

Group type: EXPERIMENTAL
Intervention: Cytokine profiles (IL-6, IFN-)
Number of subjects: 35
Study: 34693027

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34693288

Group type: EXPERIMENTAL
Intervention: Macitentan 30 mg to 300 mg once daily with TMZ
Number of subjects: 38
Study: 34693505

Group type: EXPERIMENTAL
Intervention: Tolvaptan (15 mg/day, median treatment duration 18.5 days, range 1-1130 days)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 252
Study: 34693508

Group type: EXPERIMENTAL
Intervention: Laser therapy initiated before the age of 5 years
Number of subjects: 84

Group type: COMPARATOR
Intervention: Laser therapy initiated after the age of 5 years
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Laser therapy achieving > 95% clearance
Number of subjects: 84
Study: 34693515

Group type: COMPARATOR
Intervention: DPP4i
Number of subjects: 129465

Group type: COMPARATOR
Intervention: GLP-1RA
Number of subjects: 129465

Group type: COMPARATOR
Intervention: SGLT2i
Number of subjects: 129465
Study: 34693720

Group type: EXPERIMENTAL
Intervention: Ajmaline test (1 mg/kg over 5 minutes)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (age, sex, and body surface area-matched)
Number of subjects: 24
Study: 34693725

Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisone/Prednisolone
Number of subjects: 0
Study: 34693912

Group type: EXPERIMENTAL
Intervention: Standardized mean GHBT AUC increase by 1-ppm
Number of subjects: 0
Study: 34693931

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ARV)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Longitudinal follow-up of PLWH
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Darunavir exposure
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Stavudine exposure
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Didanosine exposure
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Emtricitabine exposure
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Triglyceride levels
Number of subjects: 70
Study: 34693935

Group type: EXPERIMENTAL
Intervention: Pediatric Asthma Score (PAS) by study personnel
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pediatric Asthma Score (PAS) by triage nurse
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Average PAS score
Number of subjects: 101
Study: 34693989

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) for OCD
Number of subjects: 46

Group type: COMPARATOR
Intervention: Anxiety management (control group)
Number of subjects: 46
Study: 34693994

Group type: EXPERIMENTAL
Intervention: Adjunctive counseling by a health professional other than the physician
Number of subjects: 112159

Group type: EXPERIMENTAL
Intervention: Cost-free smoking cessation medications
Number of subjects: 112159

Group type: EXPERIMENTAL
Intervention: Tailored printed materials
Number of subjects: 112159

Group type: COMPARATOR
Intervention: Biomedical risk feedback
Number of subjects: 112159

Group type: COMPARATOR
Intervention: Training or incentives for primary care providers
Number of subjects: 112159
Study: 34694005

Group type: EXPERIMENTAL
Intervention: Staff-based interventions to change practice in outside-school hours childcare settings
Number of subjects: 4458

Group type: EXPERIMENTAL
Intervention: Staff- and parent-based interventions
Number of subjects: 4458

Group type: EXPERIMENTAL
Intervention: Staff- and child-based interventions
Number of subjects: 4458

Group type: EXPERIMENTAL
Intervention: Child-only based intervention
Number of subjects: 4458

Group type: COMPARATOR
Intervention: Physical activity interventions
Number of subjects: 4458

Group type: EXPERIMENTAL
Intervention: Online physical activity interventions
Number of subjects: 4458

Group type: EXPERIMENTAL
Intervention: Multi-component interventions with a specific physical activity goal
Number of subjects: 4458

Group type: EXPERIMENTAL
Intervention: Interventions
Number of subjects: 4458
Study: 34694234

Group type: EXPERIMENTAL
Intervention: Artificial intelligence-powered clinical decision support system (CDSS) used during visits 1 and 2
Number of subjects: 17

Group type: COMPARATOR
Intervention: Baseline (no CDSS used)
Number of subjects: 17
Study: 34694263

Group type: EXPERIMENTAL
Intervention: Alagille syndrome (ALGS)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Alpha 1 antitrypsin deficiency (A1AT)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Progressive familial intrahepatic cholestasis (PFIC)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Test norms
Number of subjects: 215
Study: 34694279

Group type: EXPERIMENTAL
Intervention: SCAN group (specialized program for screening and treating anal neoplasia)
Number of subjects: 3878

Group type: EXPERIMENTAL
Intervention: Follow-up group (including men who have sex with men)
Number of subjects: 3878

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 3878

Group type: COMPARATOR
Intervention: Men who have sex with men (not screened)
Number of subjects: 3878

Group type: COMPARATOR
Intervention: Lack of immune restoration
Number of subjects: 3878

Group type: COMPARATOR
Intervention: CDC category C
Number of subjects: 3878

Group type: COMPARATOR
Intervention: Non-men who have sex with men
Number of subjects: 3878

Group type: COMPARATOR
Intervention: Follow-up group including non-men who have sex with men
Number of subjects: 3878
Study: 34694435

Group type: EXPERIMENTAL
Intervention: Change in hs-cTnT values exceeding the biological variation defined by MID
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changes within MID
Number of subjects: 0
Study: 34694529

Group type: EXPERIMENTAL
Intervention: Sasanlimab (intravenous at 1, 3, or 10 mg/kg every 3 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sasanlimab (subcutaneous at 300 mg every 4 weeks)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sasanlimab (both intravenous and subcutaneous)
Number of subjects: 38
Study: 34694878

Group type: EXPERIMENTAL
Intervention: Dolutegravir plus an optimized background regimen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dolutegravir
Number of subjects: 0
Study: 34694909

Group type: EXPERIMENTAL
Intervention: MiniMed™ Advanced Hybrid Closed-Loop System
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34694911

Group type: EXPERIMENTAL
Intervention: Transcranial Rotating Permanent Magnet Stimulator (TRPMS), 10 consecutive 40-minute treatment sessions.
Number of subjects: 10
Study: 34695274

Group type: EXPERIMENTAL
Intervention: Cerebellar damage (measured by lesion loads and volumes)
Number of subjects: 838
Study: 34695300

Group type: EXPERIMENTAL
Intervention: Increased time spent in rehabilitation (90 to 1288 minutes per week, 3 to 7 days per week, 2 weeks to 6 months duration)
Number of subjects: 1412

Group type: COMPARATOR
Intervention: Control group (less time in rehabilitation)
Number of subjects: 1412
Study: 34695377

Group type: EXPERIMENTAL
Intervention: Y90-radioembolisation followed by nivolumab
Number of subjects: 40